Uncovering influence links in molecular knowledge networks to streamline personalized medicine

Journal of Biomedical Informatics

Volumn 52, Issue , 2014, Pages 394-405

  Shin, Dmitriy ^a,b   Arthur, Gerald ^a,b   Popescu, Mihail ^a,b,c   Korkin, Dmitry ^d   Shyu, Chi Ren ^b,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

^d Worcester Polytechnic Institute   (United States)

Author keywords

Morphoproteomics; Personalized medicine; RDF inference; Systems pathology; Theranostics

Indexed keywords

COMPLEX NETWORKS; KNOWLEDGE BASED SYSTEMS; MONTE CARLO METHODS; PROTEINS;

ACUTE LYMPHOBLASTIC LEUKEMIA; MORPHOPROTEOMICS; PERSONALIZED MEDICINES; RDF INFERENCE; RESOURCE DESCRIPTION FRAMEWORK; STRUCTURE LEARNING ALGORITHM; SYSTEMATIC LITERATURE REVIEW; THERANOSTICS;

MEDICINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALGORITHM; ARTICLE; EQUILIBRIUM CONSTANT; KNOWLEDGE BASE; LEARNING ALGORITHM; MEDLINE; ONTOLOGY; PERSONALIZED MEDICINE; PROFESSIONAL KNOWLEDGE; PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; VALIDITY; HUMAN; PHYSIOLOGY; PROCEDURES; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKER;

ALGORITHMS; BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; KNOWLEDGE BASES; PROTEIN INTERACTION MAPS; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84919628430     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2014.08.003     Document Type: Article

References (92)

1. Tanaka H. Omics-based medicine and systems pathology. A new perspective for personalized and predictive medicine. Methods Inform Med 2010, 49(2):173-185.
2. Sung N.S., Crowley W.F., Genel M., Salber P., Sandy L., Sherwood L.M., et al. Central challenges facing the national clinical research enterprise. JAMA 2003, 289(10):1278-1287.
3. Warner S. Diagnostics+therapy=theranostics: strategy requires teamwork, partnering, and tricky regulatory maneuvering. The Scientist 2004, (August).
4. Taylor C.R. IHC and the WHO classification of lymphomas: cost effective immunohistochemistry using a deductive reasoning 'decision tree' approach. Appl Immunohistochem Mol Morphol 2009, 17(5):366-374.
5. Ibrahim N.B., Briggs J.C. Immunohistochemistry of gastrointestinal lymphomas. Histopathology 1988, 12(2):231-233.
6. Vollmer R.T. Differential diagnosis in immunohistochemistry with Bayes theorem. Am J Clin Pathol 2009, 131(5):723-730.
7. al-Okati D., Ibrahim N.B., Briggs J.C. Immunohistochemistry in sweat gland tumours. Histopathology 1991, 19(6):576-577.
8. Terenghi G., Riveros-Moreno V., Hudson L.D., Ibrahim N.B., Polak J.M. Immunohistochemistry of nitric oxide synthase demonstrates immunoreactive neurons in spinal cord and dorsal root ganglia of man and rat. J Neurol Sci 1993, 118(1):34-37.
9. Brown R.E. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009, 133(4):568-579.
10. Brown R.E., Lun M., Prichard J.W., Blasick T.M., Zhang P.L. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 2004, 34(3):251-262.
11. Brown R.E., Zhang P.L., Lun M., Zhu S., Pellitteri P.K., Riefkohl W., et al. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 2006, 36(3):273-282.
12. Brown R.E., Zotalis G., Zhang P.L., Zhao B. Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 2008, 1(4):333-342.
13. Zenali M.J., Zhang P.L., Bendel A.E., Brown R.E. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab Sci 2009, 39(2):160-166.
14. Brown R.E., Tan D., Taylor J.S., Miller M., Prichard J.W., Kott M.M. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates. Ann Clin Lab Sci 2007, 37(2):141-147.
15. Brown R.E., Law A. Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci 2006, 36(4):421-426.
16. Takemoto S., Ushijima K., Kawano K., Yamaguchi T., Terada A., Fujiyoshi N., et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 2009, 101(6):967-972.
17. Feng W., Duan X., Liu J., Xiao J., Brown R.E. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2009, 2(3):249-260.
18. Brown R.E. Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma. Ann Clin Lab Sci 2004, 34(4):397-399.
19. Feng W., Brown R.E., Trung C.D., Li W., Wang L., Khoury T., et al. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 2008, 38(3):195-209.
20. Brown R.E., Bostrom B., Zhang P.L. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004, 34(2):203-205.
21. Liu J, Brown RE. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants, August 2011.
22. Brown R.E. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005, 2(3):337-348.
23. Shen Q., Stanton M.L., Feng W., Rodriguez M.E., Ramondetta L., Chen L., et al. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol 2010, 4(1):13-21.
24. Lin F., Zhang P.L., Yang X.J., Prichard J.W., Lun M., Brown R.E. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006, 36(3):283-293.
25. Zhang P.L., Quiery A.T.J., Blasick T.M., Brown R.E. Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment. Ann Clin Lab Sci 2007, 37(1):34-38.
26. Liu J., Brown R.E. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci 2010, 40(3):211-217.
27. Subbiah V., Naing A., Brown R.E., Chen H., Doyle L., LoRusso P., et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS ONE 2011, 6(4):e18424.
28. Rosai J, Rosai J. Rosai and Ackerman's surgical pathology; 2011.
29. Shin D., Arthur G., Caldwell C., Popescu M., Petruc M., Diaz-Arias A., et al. A pathologist-in-the-loop IHC antibody test selection using the entropy-based probabilistic method. J Pathol Inf 2012, 3(1):1.
30. Croft D., Croft D., Mundo A.F., Mundo A.F., Haw R., Haw R., et al. The Reactome pathway knowledgebase. Nucl Acids Res 2013, 42(1):D472-D477.
31. "BioCarta - Charting Pathways of Life," biocarta.com. [Accessed: 17.11.11]. http://www.biocarta.com/genes/index.asp.
32. Karp P., Ouzounis C., Moore-Kochlacs C., Goldovsky L., Kaipa P., Ahrén D., et al. Expansion of the BioCyc collection of pathway/genome databases to 160 genomes. Nucl Acids Res 2005, 33(19):6083-6089.
33. Schaefer C., Anthony K., Krupa S., Buchoff J., Day M., Hannay T., et al. PID: the pathway interaction database. Nucl Acids Res 2009, 37(1):D674-D679.
34. Consortium T.U. The Universal Protein Resource (UniProt) in 2010. Nucl Acids Res 2010, 38(1):D142-D148.
35. Prasad K., Kandasamy K., Pandey A. Human protein reference database and human proteinpedia as discovery tools for systems biology. Reverse Chem Genet 2009, 577:67-79.
36. Manola F, Miller E, editors, {RDF Primer}, no. 3. World Wide Web Consortium; 2004.
37. Sahoo S.S., Bodenreider O., Rutter J.L., Skinner K.J., Sheth A.P. An ontology-driven semantic mashup of gene and biological pathway information: application to the domain of nicotine dependence. J Biomed Inform 2008, 41(5):752-765.
38. Ruttenberg A., Clark T., Bug W., Samwald M., Bodenreider O., Chen H., et al. Advancing translational research with the Semantic Web. BMC Bioinform 2007, 8(May):S2. Methodology.
39. Gudivada R.C., Gudivada R., Qu X.A., Chen J., Jegga A.G., Neumann E.K., et al. Identifying disease-causal genes using Semantic Web-based representation of integrated genomic and phenomic knowledge. J Biomed Inform 2008, 41(5):717-729.
40. Dumontier M., Villanueva-Rosales N. Towards pharmacogenomics knowledge discovery with the semantic web. Briefings Bioinform 2009, 10(2):153-163.
41. Holford M.E., Rajeevan H., Zhao H., Kidd K.K., Cheung K.-H. Semantic Web-based integration of cancer pathways and allele frequency data. Cancer Inform 2009, 8:19-30.
42. Luciano J.S., Andersson B., Batchelor C. The translational medicine ontology and knowledge base: driving personalized medicine by bRIIGging the gap between bench and bedside. J Biomed 2011, (January).
43. Dumontier M., Andersson B., Batchelor C. The translational medicine ontology: driving personalized medicine by bRIIGging the gap from bedside to bench. Bio-Ontologies 2010, (January).
44. Wang H.-Q., Li J.-S., Zhang Y.-F., Suzuki M., Araki K. Creating personalised clinical pathways by semantic interoperability with electronic health records. Artif Intell Med 2013, 58(2):81-89.
45. Wild D.J., Ding Y., Sheth A.P., Harl L., Harland L., Gifford E.M., et al. Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. Drug Discovery Today 2012, 17(9):469-474.
46. Jiang G, Wang C, Zhu Q, Chute CG. A framework of knowledge integration and discovery for supporting pharmacogenomics target predication of adverse drug events: a case study of drug-induced long QT syndrome. In: AMIA joint summits on translational science proceedings amia summit on translational science, vol. 2013, January 2013. p. 88-92.
47. Wang Z., Sagotsky J., Taylor T., Shironoshita P., Deisboeck T.S. Accelerating cancer systems biology research through Semantic Web technology. Wiley interdisciplinary reviews. Syst Biol Med 2013, 5(2):135-151.
48. Meldolesi E., van Soest J., Dinapoli N., Dekker A., Damiani A., Gambacorta M.A., et al. An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2014, (May):1-4.
49. Douali N., Abdennour M., Zucker J.D., Jaulent M.-C. Formalization of clinical practice guidelines: nonalcoholic steatohepatitis diagnosis model-related personalized medicine. Eur J Biomed Infom 2014, 10(1).
50. Douali N., De Roo J., Jaulent M.-C. Clinical diagnosis support system based on case based fuzzy cognitive maps and semantic web. Stud Health Technol Inform 2012, 180:295-299.
51. Douali N., Csaba H., De Roo J., Papageorgiou E.I., Jaulent M.-C. Diagnosis support system based on clinical guidelines: comparison between case-based fuzzy cognitive maps and Bayesian networks. Comput Methods Programs Biomed 2014, 113(1):133-143.
52. Prud'hommeaux E, Seaborne A. SPARQL query language for RDF; 2008.
53. McGuinness D, van Harmelen F. OWL Web ontology language overview; 2004.
54. Horrocks I, Patel-Schneider P, Boley H, Tabet S, Grosof B, Dean M. {SWRL}: a Semantic Web Rule Language Combining {OWL} and {RuleML}; 2004.
55. Sahoo S.S., Zeng K., Bodenreider O., Sheth A. From "glycosyltransferase" to 'congenital muscular dystrophy': integrating knowledge from NCBI Entrez Gene and the Gene Ontology. Stud Health Technol Inform 2007, 129(2):1260-1264.
56. Croft D., O'Kelly G., Wu G., Haw R., Gillespie M., Matthews L., et al. Reactome: a database of reactions, pathways and biological processes. Nucl Acids Res 2011, 39(Database issue):D691-D697.
57. Baader F. The description logic handbook: theory, implementation, and applications 2007, CambRIIGge University Press, CambRIIGge; New York.
58. Semantic Web for the Working Ontologist; 2011.
59. Pearl J. Causality: models, reasoning, and inference 2000, CambRIIGge University Press, CambRIIGge, UK; New York, pp. xvi-384.
60. Koller D, Friedman N. In: Probabilistic graphical models: principles (text only) by Koller D, Friedman N, editors. The MIT Press; 2009.
61. Spirtes C., Glymour P., Scheines R. Causation, prediction and search 2001, The MIT Press.
62. Demir E., Cary M.P., Paley S., Fukuda K., Lemer C., Vastrik I., et al. The BioPAX community standard for pathway data sharing. Nat Biotechnol 2010, 28(9):935-942.
63. Scheines R., Spirtes P., Glymour C., Meek C., Richardson T. The TETRAD project: constraint based aids to causal model specification. Multivariate Behav Res 1998, 33(1):65-117.
64. Verma T, Pearl J. "An algorithm for deciding if a set of observed independencies has a causal explanation", presented at the Eighth Conference on Uncertainty in Artificial Intelligence; 1992. p. 13.
65. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. The WEKA data mining software: an update. SIGKDD Explor News 2009, 11(1).
66. Wilkinson K, Sayers C, Kuno H. "Efficient RDF storage and retrieval in Jena2", presented at the proceedings of SWDB; 2003.
67. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15(7):807-826.
68. Khatib H., Huang W., Mikheil D., Schutzkus V., Monson R.L. Effects of signal transducer and activator of transcription (STAT) genes STAT1 and STAT3 genotypic combinations on fertilization and embryonic survival rates in Holstein cattle. J Dairy Sci 2009, 92(12):6186-6191.
69. UniProt Consortium. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2012;40(Database issue):D71-D75.
70. Zhang X., Yue P., Fletcher S., Zhao W., Gunning P.T., Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 2010, 79(10):1398-1409.
71. Jiang R., Jin Z., Liu Z., Sun L., Wang L., Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagnosis Ther 2011, 15(6):347-352.
72. Morikawa T., Baba Y., Yamauchi M., Kuchiba A., Nosho K., Shima K., et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011, 17(6):1452-1462.
73. Huang C., Huang R., Chang W., Jiang T., Huang K., Cao J., et al. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 2012, 59(1):52-61.
74. Seo H.-S., Choi H.-S., Kim S.-R., Choi Y.K., Woo S.-M., Shin I., et al. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem 2012, 366(1):319-334.
75. Teng S.-P., Hsu W.-L., Chiu C.-Y., Wong M.-L., Chang S.-C. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet J 2012, (March).
76. Umehara S., Fujiwara H., Shiozaki A., Todo M., Furutani A., Yoneda M., et al. PSK induces apoptosis through the inhibition of activated STAT3 in human esophageal carcinoma cells. Int J Oncol 2012, 41(1):61-66.
77. Katz E., Sims A.H., Sproul D., Caldwell H., Dixon M.J., Meehan R.R., et al. Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 2012, (June).
78. Liu D.-B., Hu G.-Y., Long G.-X., Qiu H., Mei Q., Hu G.-Q. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin 2012, 33(5):682-690.
79. Nair R.R., Tolentino J.H., Hazlehurst L.A. Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2012, 2:30.
80. Swiatek-Machado K., Mieczkowski J., Ellert-Miklaszewska A., Swierk P., Fokt I., Szymanski S., et al. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther 2012, 13(8):657-670.
81. Zhang X., Yue P., Page B.D.G., Li T., Zhao W., Namanja A.T., et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012, 109(24):9623-9628.
82. Bonetto A., Aydogdu T., Jin X., Zhang Z., Zhan R., Puzis L., et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012, (June).
83. Han G., Yu J.Y., Chen Y.D., Cao X.L., Zhu J., Wang W., et al. The usefulness of phosphorylated-signal transduction and activators of transcription 3 in detecting prostate cancer from negative biopsies. Eur J Surg Oncol 2012, 38(4):367-373.
84. Koskela H.L.M., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmäki H., Andersson E.I., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012, 366(20):1905-1913.
85. Yang H., Xu A.-P., Lv J., Liu Y. Expression of STAT3 and PIAS3 in renal tissues of MRL/lpr mice. Nan Fang Yi Ke Da Xue Xue Bao 2012, 32(6):821-825.
86. Maglott D., Ostell J., Pruitt K.D., Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucl Acids Res 2005, 33(Database issue).
87. Vignais M.L., Sadowski H.B., Watling D., Rogers N.C., Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 1996, 16(4):1759-1769.
88. Herling M., Patel K.A., Weit N., Lilienthal N., Hallek M., Keating M.J., et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009, 114(21):4675-4686.
89. Bellucci R., Nguyen H.-N., Martin A., Heinrichs S., Schinzel A.C., Hahn W.C., et al. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 2012, 122(7):2369-2383.
90. Li J., Favata M., Kelley J.A., Caulder E., Thomas B., Wen X., et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010, 12(1):28-38.
91. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120(14):2843-2852.
92. Maude S.L., Tasian S.K., Vincent T., Hall J.W., Sheen C., Roberts K.G., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120(17):3510-3518.